🏛️ Verified NIH Record • Updated 2025-07-29
Study of SGR-3515 In Participants With Advanced Solid Tumors. (NCT06463340)
A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Schrödinger, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Yale University, Yale Cancer Center — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Yale University, Yale Cancer Center — New Haven, Connecticut
- Northwestern University — Chicago, Illinois
- University of Michigan — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Icahn School of Medicine at Mount Sinai — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Sarah Cannon Research Institute — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center/Henry-Joyce Cancer Clinic — Nashville, Tennessee
- University of Texas Southwestern — Dallas, Texas
- NEXT Virginia — Fairfax, Virginia
- Princess Margaret Cancer Centre — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (503) 299-1150
Email: sdgr-trials-group@schrodinger.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.